Octreotide Efficacious for Preventing Rebleeding in Small Bowel Angioectasia

intestine with blood clot
Researchers examined the efficacy of octreotide for preventing rebleeding as a result of small bowel angioectasia.

Octreotide is efficacious for preventing rebleeding among patients with small bowel angioectasia (SBA), according to a study published in Revista de Gastroenterología de Mexico.

Researchers conducted a single-center, comparative study, which identified 132 patients with SBA. A total of 52 patients with acute or chronic bleeding due to SBA were included in the study. Of these, 16 patients received octreotide 100 mcg subcutaneously per day, and 36 were enrolled as control individuals. Patients in the treatment group and nontreatment group had a mean age of 73.5±13.3 and 66.1±6.6 years, respectively.

Exclusion criteria for the remaining 80 patients included having received other treatments, such as thalidomide, lanreotide, or surgical resection. Patients were monitored monthly for the first 6 months, then every 3 to 6 months through the remainder of the study.

The primary outcome of the study was rebleeding, which was defined as a decrease in hemoglobin greater than 2g/dl, a blood transfusion requirement, visible blood in the stool, or the need for parenteral administration of iron. Secondary outcomes included hospital readmission and bleeding-related death.

Despite having a higher age at baseline, patients in the treatment vs nontreatment group had a significantly lower rate of rebleeding (25% vs 72.2%, P =.002). Patients who received vs did not receive octreotide also had lower rates of blood transfusion (6.3% vs 38.9%, P =.021) and hospital readmission (6.3% vs 36.1%, P =.04). The probability of remaining free from rebleeding at 2 years was 79% for patients who received octreotide and 34.6% for patients in the control group.

Study limitations included the single-center design; the small, homogenous sample size; a lack of placebo; and using nonblinded evaluations. There was also insufficient follow-up in the treatment group.

“In conclusion, the results of our study suggest that octreotide is effective in preventing rebleeding due to SBA,” the study authors noted. “The drug was well tolerated and was associated with reduced hospital readmissions related to bleeding.”


Del Cueto-Aguilera AN, García-Compeán D, Jiménez-Rodríguez AR, et al. Efficacy of octreotide in bleeding recurrence from small bowel angioectasia: a comparative study. Rev Gastroenterol Mex. Published online June 9, 2022. doi:10.1016/j.rgmx.2021.02.012